מזומנים למניה אחת Lisata Therapeutics, Inc. (LSTA)

סמל תאגידי ולוגו של Lisata Therapeutics Inc. (LSTA)

Lisata Therapeutics (LSTA) relies on delegating clinical trials to global CRO networks to optimize costs. This chart from the GURU.Markets terminal illustrates cash per share for the issuer, where 26.14 defines the current status of the parameter. Growth potential is based on the licensing of the drug delivery platform and streamlined component logistics, which guarantee the preservation of drug properties.

יתרות מזומנים למניה Lisata Therapeutics (LSTA): לתקופה 28.04.2023 - 20.11.2026

פילוחים אנליטיים של חברת Lisata Therapeutics

- שער מניה ותחזית מחירי מומחים:
- פרטי פוזיציית מזומנים ותזרימי מזומנים:
ניתוח מסכם של החברה:LSTA, Lisata
מוצר המיוצר על ידי lisata.com

A comparative analysis of liquid assets allows an investor to determine the real value of a single certificate through the prism of available capital. This metric is calculated by dividing the total cash balance by the number of shares outstanding. For Lisata Therapeutics (LSTA), this resource is critical due to colossal oncology R&D expenditures and clinical phase risks. Capital efficiency determines the business's survival horizon. By analyzing the cash per share metric, one can assess the probability of the company's long-term scaling.